1. South Korea Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
HLB Life Science Co.,Ltd.

HLB Life Science Co.,Ltd.

KKRX:067630
3,515.00
KRW
+10.00
(+0.29%)
-414.95EPS
463.63BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1,057.03
1,151.04
722.43
738.36
1,869.5
1,606.62
1,158.25
438.18
508.37
979.38
897.35
293.65
375.48
422.34
Basic EPS, GAAP
-215.79
44.17
-450.57
-21.88
136.31
-285.2
-77.25
-266.34
-467.1
-533.76
-54.79
55
-819
-413.65
Free Cash Flow per Basic Share
151.88
311.36
-132.95
-62.47
-10.7
-338.8
-283.15
-89.73
-158.65
-407.1
-288.81
-532.91
-401.11
-356.37
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
370.22
423.31
460.17
491.98
833.07
2,523.68
3,186.15
2,740.22
2,315.7
2,292.8
2,141.88
3,270.06
2,440.36
2,409.58
Tangible Book Value per Share
368.48
255.7
441.88
417.32
799.88
1,217.71
2,266.52
2,002.3
1,724.91
1,399.69
1,624.03
2,902.45
2,015.74
1,989.05
Basic Weighted Avg Shares
19
32
38
57
57
64
98
209
105
102
109
112
122
122
Sales/Revenue/Turnover
19,956
36,560
27,323
42,234
106,445
102,476
114,019
91,797
53,494
99,591
97,990
32,771
45,752
51,512
Operating Margin (%)
-16.04
3.97
-35.48
-2.7
0.95
-7.59
-3.92
-8.73
-34.26
-20.03
-25.02
-60.93
-45.95
-42.33
Depreciation Expense
556
537
714
348
319
346
1,902
2,255
2,484
5,223
7,696
5,901
5,247
6,518
Net Income, GAAP
-4,074
1,403
-17,041
-1,251
7,761
-18,191
-7,605
-55,797
-49,152
-54,277
-5,983
6,138
-99,794
-50,452
Effective Tax Rate (%)
- -
- -
- -
- -
0.93
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-20.42
3.84
-62.37
-2.96
7.29
-17.75
-6.67
-60.78
-91.88
-54.5
-6.11
18.73
-218.12
-97.94
Working Capital
6,041
1,890
17,485
18,239
37,900
190,448
183,822
163,464
143,286
133,991
11,586
101,745
-49,881
-58,409
LT Debt
6,896
4,342
2,156
17,635
8,719
80,074
10,575
11,014
3,953
137,021
51,834
82,722
56,330
55,930
Total Equity
11,034
13,441
25,895
27,685
52,826
206,114
334,425
287,744
246,612
236,067
231,213
398,825
297,742
293,981
Return on Invested Capital (%)
- -
- -
- -
- -
1.78
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
16.15
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-45.08
11.47
-86.64
-4.67
19.28
-14.17
-2.83
-17.97
-18.43
-22.57
-2.57
1.95
-28.69
-15.91

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
97,952
104,027
108,136
LT Borrowings
56,249
54,473
53,917
LT Finance Leases
196
1,857
2,013
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
122
122
122
Market Capitalization
400,268
472,158
463,628

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
101,793
68,935
70,697
Cash, Cash Equivalents & STI
24,870
13,878
19,748
Accounts Receivable, Net
14,446
14,975
18,277
Inventories
5,670
6,791
5,860
Total Current Liabilities
108,889
118,815
129,106
Payables & Accruals
- -
- -
- -
ST Debt
97,952
104,027
108,136
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
46.27%
5.3%
-25.35%
Free Cash Flow
351.47%
36.74%
-17.82%
Net Income, GAAP
-259.07%
-403.78%
-1,725.88%
Sales/Revenue/Turnover
21.05%
3.18%
39.61%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
23,894
7,477
8,194
28,682
32,771
2025
9,439
11,769
13,596
10,948
45,752
2026
15,199
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,316.93
-1,334
591
-490.13
55
2025
-470
-213
-301
164.82
-819
2026
-63.98
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sung-Bo Sim
Full Time Employees
180
Sector
Distribution services
Industry
Medical distributors
Address
51-9, Dongtancheomdansaneop 1-ro Hwaseong-si GY South Korea
IPO Date
Nov 25, 2008
Website
hlb-ls.com
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally; it develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors, and Pyrotinib, an anticancer drug inhibiting cancer cell proliferation, division, and survival; the company manufactures and sells disposable syringes and engages in waste heat recovery, cogeneration power generation, solar energy, photovoltaic power generation, bioenergy, geothermal energy, waste energy, wind power, and fuel cell businesses, as well as energy efficiency projects, heating system improvements, and renewable energy facility construction. Founded in 1998 and headquartered in Hwaseong-si, South Korea, the company, formerly Energy Solutions Co., Ltd., changed its name in December 2015 and operates primarily in pharmaceuticals wholesale and distribution through subsidiaries offering targeted therapy, cell therapy, new drug development, and medical devices. Recent developments include its integration within the HLB Group, which raised $145 million in November 2025 to advance its global anti-cancer drug pipeline featuring Rivoceranib and the UNITE immunotherapy platform, and pursued strategic acquisitions such as Verismo Therapeutics via merger in December 2024 to bolster cell therapy capabilities, alongside HLB Genex's $11.1 million acquisition of NeuroTobe in April 2025 for brain disease treatments.